艾乐替尼一线治疗ALK阳性晚期非小细胞肺癌显著优于克唑替尼
The Journal of Evidence-Based Medicine（2018）
Abstract
1 文献来源
Hida T,Nokihara H,Kondo M,et al. Alectinib versus Crizotinib in patients with ALK?positive non?small?cell lung cancer(J?ALEX):An open?label,randomised phase 3 trial[J]. Lancet,2017,390(10089):29-39.
2 证据水平
1b.
3 背景
?ALK 抑制剂(克唑替尼、艾乐替尼)对ALK阳性的非小细胞肺癌(non?small cell lung cancer,NSCLC)患者疗效良好;
?Ⅰ/Ⅱ期单臂研究(AF?001JP 等)已证实艾乐替尼缓解率高、无进展生存期(progression?freesurvival,PFS)长,对克唑替尼耐药的患者仍有效;
?艾乐替尼缺少Ⅲ期临床研究数据,尚无直接比较克唑替尼与艾乐替尼疗效何者更优的临床研究数据.
MoreKey words
non-small cell lung cancer,ALK-positive,Alectinib,Crizotinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined